A multi-institutional research team led by the Indiana University School of Medicine has secured a $9 million grant to investigate how immune cell aging contributes to the onset and progression of Parkinson’s disease. The project, supported by Aligning Science Across Parkinson’s (ASAP) and The Michael J. Fox Foundation for Parkinson’s Research, will examine immune-cell exhaustion in both idiopathic and familial cases to identify new targets for precision therapies.
How Does Immune System Aging Influence Parkinson’s?
Age is the primary risk factor for Parkinson’s disease, yet the specific connection between immune system decline and neurodegeneration remains largely unmapped. According to Malú Gámez Tansey, PhD, professor of neurology at IU School of Medicine and the project’s lead primary investigator, the research aims to treat Parkinson’s by addressing dysregulated immune processes. By studying “immune-cell exhaustion”—a state where immune cells lose their ability to function effectively over time—the team hopes to mirror the precision-medicine approach currently utilized in oncology to better predict disease progression.
Parkinson’s disease affects more than 1.1 million people in the United States. In 2024, the annual economic burden, including healthcare, disability, and caregiving costs, reached $82 billion.
Why is Cross-Institutional Collaboration Necessary?
Parkinson’s disease is highly heterogeneous, meaning it manifests differently across the patient population. To address this, the Collaborative Research Network (CRN) is scaling its efforts to create a standardized toolkit for global researchers. Richard Smeyne, PhD, chair of the Department of Neuroscience at Thomas Jefferson University, notes that the complexity of the disease exceeds the capacity of any single institution. The team combines expertise from IU School of Medicine, Columbia University, Thomas Jefferson University, and Tulane University to bridge the gap between pre-clinical laboratory findings and clinical patient outcomes.
What Role Do Lifestyle and Environment Play?
While biological aging is a fixed factor, the research team is also investigating whether environmental and lifestyle variables accelerate immune cell burnout. Rebecca Wallings, DPhil, assistant professor of neurology at IU School of Medicine, explains that identifying measurable markers of immune aging could provide a “launch point” for future immunotherapies. By mapping these biological blueprints, the team aims to determine why the disease follows a different trajectory for different individuals.
Data-Driven Approaches to Disease Mapping
The project integrates biostatistics to manage complex health data, with Travis S. Johnson, PhD, serving as the project’s data manager. This focus on high-quality, standardized data is intended to reduce technical hurdles that have historically stalled drug development. By creating a common baseline for the global research community, the initiative seeks to transition from generalized treatments to therapies tailored to an individual’s specific immune profile.
For those tracking the latest developments in neuroimmunology, monitoring the Michael J. Fox Foundation research portal provides the most accurate updates on how these clinical trial phases are evolving.
Frequently Asked Questions
- What is immune-cell exhaustion in the context of Parkinson’s?
It refers to the natural decline of immune cell function as individuals age, which researchers believe may contribute to the development or worsening of Parkinson’s disease. - Who is funding this research?
The project is funded by Aligning Science Across Parkinson’s (ASAP) in partnership with The Michael J. Fox Foundation for Parkinson’s Research. - Why is this project different from previous studies?
Unlike singular studies, this project utilizes a multi-institutional, interdisciplinary network to create a standardized “biological blueprint” that can be used by the global scientific community.
Are you interested in how precision medicine is changing the landscape of neurodegenerative care? Subscribe to our newsletter for updates on this study and other breakthroughs in Parkinson’s research.
